A Timeline Setback for Roche
- Roche reported a significant delay in their Phase 1/2 clinical trials, which aim to evaluate the safety and effectiveness of Mosunetuzumab (BTCT4465A) alongside Polatuzumab Vedotin for B-Cell Non-Hodgkin Lymphoma patients. Originally scheduled to conclude on September 30, 2023, the trial is now projected to end on October 31, 2024, marking a 13-month extension.
- BTCT4465A is a bispecific antibody, which means that it has two binding sites: one for CD20 and one for the Fc receptor on immune cells. This allows the drug to bring immune cells together with B cells, which can lead to the destruction of the B cells.
Diving Deeper into Roche’s Mosunetuzumab Program and Beyond
- Their Mosunetuzumab program boasts seven clinical trials spanning across Phase 1, Phase 1/2, and Phase 3, with diverse aims, from evaluating safety and tolerability to understanding pharmacokinetics and gauging efficacy for various drug combinations in tackling different B-cell Non-Hodgkin Lymphoma variants.
- Beyond this, Roche is putting several other investigational compounds, including Atezolizumab, tiragolumab, and Crovalimab, under the lens. These span from initial trials focusing on safety to late-stage trials assessing effectiveness in larger groups, with expected finish dates set between August 2020 and March 2031.
Who's On the B-cell Non-Hodgkin Lymphoma Frontline? A Glimpse at Key Players
- ADC Therapeutics, a Swiss-based oncology-focused biotechnology company, is testing Loncastuximab Tesirine. Trials in Phases 1 and 2 are projected to conclude by February 2025.
- AstraZeneca has its research lens on Capivasertib, set for completion in a Phase 2 trial by December 2023.
- Novartis puts Tisagenlecleucel under review in mid to late-stage trials, due by dates from October 2022 to February 2026.
Sources: Clinicaltrials.gov, PubMed, Press Releases, and AppliedXL. This report is generated algorithmically and may not cover all ongoing industry-sponsored trials. AppliedXL implements rigorous AI vetting processes but cannot guarantee the completeness of all insights.